Inivata Ltd (Inivata), a subsidiary of NeoGenomics Inc., is a cancer genomics company that harnesses liquid biopsy platforms to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst - Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotide variants, insertions and deletions, and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer; and InVisionSeq test. Inivata collaborates with industry and academic researchers to develop new clinical applications for liquid biopsy and ctDNA analysis. The company operates across the UK and the US. Inivata is headquartered in Cambridge, Cambridgeshire, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Inivata Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Inivata Ltd Company Overview
- Inivata Ltd Company Snapshot
- Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Inivata Ltd - Pipeline Analysis Overview
- Inivata Ltd - Key Facts
- Inivata Ltd - Major Products and Services
- Inivata Ltd Pipeline Products by Development Stage
- Inivata Ltd Ongoing Clinical Trials by Trial Status
- Inivata Ltd Pipeline Products Overview
- InVision ctDNA Assay - EGFR-Mutant NSCLC
- InVision ctDNA Assay - EGFR-Mutant NSCLC Product Overview
- InVision ctDNA Assay - Metastatic Breast Cancer
- InVision ctDNA Assay - Metastatic Breast Cancer Product Overview
- InVision ctDNA Assay - NSCLC
- InVision ctDNA Assay - NSCLC Product Overview
- InVision ctDNA Assay - Pancreatic Cancer
- InVision ctDNA Assay - Pancreatic Cancer Product Overview
- InVision ctDNA Assay - Stage III/IV NSCLC
- InVision ctDNA Assay - Stage III/IV NSCLC Product Overview
- RaDaR Assay
- RaDaR Assay Product Overview
- RaDaR Assay Clinical Trial
- Inivata Ltd - Key Competitors
- Inivata Ltd - Key Employees
- Inivata Ltd - Locations And Subsidiaries
- Head Office
- Recent Developments
- Inivata Ltd, Recent Developments
- Dec 27, 2023: Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
- Dec 05, 2023: NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
- Jul 27, 2023: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
- Jun 15, 2023: Neogenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
- Jun 05, 2023: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2 - Breast Cancer
- May 30, 2023: NeoGenomics to showcase the transformational impact of RaDaR assay for molecular residual disease and recurrence monitoring at ASCO
- Apr 06, 2023: NeoGenomics to share nine abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
- Mar 16, 2023: NeoGenomics announces commercial availability of the RaDaR Molecular Residual Disease Test
- Feb 06, 2023: RaDaR(R) assay demonstrates clinical potential for helping Oncologists determine whether or not muscle-invasive bladder cancer patients undergo radical surgery
- Nov 21, 2022: RaDaR(R) Assay demonstrates clinical potential for detecting disease recurrence across all types of early breast cancer, including triple negative disease
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Inivata Ltd Pipeline Products by Equipment Type
- Inivata Ltd Pipeline Products by Indication
- Inivata Ltd Ongoing Clinical Trials by Trial Status
- Inivata Ltd, Key Facts
- Inivata Ltd, Major Products and Services
- Inivata Ltd Number of Pipeline Products by Development Stage
- Inivata Ltd Pipeline Products Summary by Development Stage
- Inivata Ltd Ongoing Clinical Trials by Trial Status
- Inivata Ltd Ongoing Clinical Trials Summary
- InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status
- InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description
- InVision ctDNA Assay - Metastatic Breast Cancer - Product Status
- InVision ctDNA Assay - Metastatic Breast Cancer - Product Description
- InVision ctDNA Assay - NSCLC - Product Status
- InVision ctDNA Assay - NSCLC - Product Description
- InVision ctDNA Assay - Pancreatic Cancer - Product Status
- InVision ctDNA Assay - Pancreatic Cancer - Product Description
- InVision ctDNA Assay - Stage III/IV NSCLC - Product Status
- InVision ctDNA Assay - Stage III/IV NSCLC - Product Description
- RaDaR Assay - Product Status
- RaDaR Assay - Product Description
- RaDaR Assay - Liquid Biopsy for Minimal Residual Disease Detection in Head and Necksquamous Cell Carcinoma (LIONESS) Study
- RaDaR Assay - SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study
- Inivata Ltd, Key Employees
- Glossary
- Inivata Ltd Pipeline Products by Equipment Type
- Inivata Ltd Pipeline Products by Development Stage
- Inivata Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DiagNodus Ltd
- Binx Health Inc
- ANGLE Plc
- ConvaTec Group Plc
- Sekisui Diagnostics UK Ltd
